

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 2

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-12 (canceled)

Claim 13 (previously amended): A method of obtaining glial cells comprising:

(a) isolating glial restricted precursor cells from central nervous system tissue by negative immunoselection of E-NCAM positive cells followed by positive immunoselection with an A2B5 antibody, said glial restricted precursor cells being immunonegative for PDGF- $\alpha$  receptor, PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen; and

(b) plating said isolated glial restricted precursor cells of step (a) under differentiating conditions, thereby causing said isolated glial restricted precursor cells to differentiate into glial cells.

Claim 14 (currently amended): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of a factor fetal calf serum that promotes differentiation into non-process bearing A2B5-GFAP<sup>+</sup> astrocytes and said glial cells are A2B5-GFAP<sup>+</sup> astrocytes.

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 3

Claim 15: (canceled)

Claim 16 (currently amended): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of ~~a factor~~ ciliary neurotrophic factor and basic fibroblast growth factor that promotes differentiation into process bearing A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes and said glial cells are A2B5<sup>+</sup>GFAP<sup>+</sup> astrocytes.

Claim 17: (canceled)

Claim 18 (currently amended): The method of claim 13 wherein said differentiating conditions comprise addition to growth medium of an effective amount of ~~a factor~~ platelet-derived growth factor and thyroid hormone (T3) that promotes differentiation into oligodendrocytes and said glial cells are oligodendrocytes.

Claims 19-48 (canceled)

Claim 49 (previously amended): A method for continuously propagating glial restricted precursor cells immunonegative for PDGF- $\alpha$  receptor, PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen comprising the steps of:

Attorney Docket No.: UT-0030  
Inventors: Rao et al.  
Serial No.: 09/736,728  
Filing Date: December 14, 2000  
Page 4

(a) isolating glial restricted precursor cells from central nervous system tissue by negative immunoselection of E-NCAM positive cells followed by positive immunoselection with an A2B5 antibody, said glial restricted precursor cells being immunonegative for PDGF- $\alpha$  receptor, PDGF- $\beta$  receptor, and Ran-2 antigen, not labeled with R24 anti-GD3 antibody, and immunopositive for A2B5 antigen; and

(b) culturing said isolated glial restricted precursor cells of step (a) *in vitro* in the presence of minimal essential salts and effective amounts of platelet derived growth factor and fibroblast growth factor.